These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36468717)

  • 21. Effect of generic-only drug benefits on seniors' medication use and financial burden.
    Tseng CW; Brook RH; Keeler E; Steers WN; Waitzfelder BE; Mangione CM
    Am J Manag Care; 2006 Sep; 12(9):525-32. PubMed ID: 16961441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence.
    Gagne JJ; Polinski JM; Jiang W; Dutcher SK; Xie J; Lii J; Fulchino LA; Kesselheim AS
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):944-52. PubMed ID: 27102378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.
    Spence MM; Nguyen LM; Hui RL; Chan J
    Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness of generic versus brand-name antiepileptic medications.
    Gagne JJ; Kesselheim AS; Choudhry NK; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
    Epilepsy Behav; 2015 Nov; 52(Pt A):14-8. PubMed ID: 26386779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physician use of brand versus generic drug names in 1993-1994 and 2003-2004.
    Kwo EC; Kamat P; Steinman MA
    Ann Pharmacother; 2009 Mar; 43(3):459-68. PubMed ID: 19261956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
    Rathe JØ
    Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Power of Labeling in Nocebo Effects.
    Faasse K; Martin LR
    Int Rev Neurobiol; 2018; 139():379-406. PubMed ID: 30146055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Converting patients from brand-name clozapine to generic clozapine.
    Sajbel TA; Carter GW; Wiley RB
    Ann Pharmacother; 2001 Mar; 35(3):281-4. PubMed ID: 11261523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs.
    Ito Y; Hara K; Yoo BK; Tomio J; Kobayashi Y
    BMC Health Serv Res; 2019 Nov; 19(1):780. PubMed ID: 31675967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of information for generic drugs based on importance and necessity].
    Iijima H; Kamei M; Koshimizu T; Shiragami M
    Yakugaku Zasshi; 2005 Sep; 125(9):739-47. PubMed ID: 16141694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
    Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
    Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Glaucoma Patients' Switch from a 2% Dorzolamide/0.5% Timolol Fixed-Combination Brand-Name Drug to Its Generic Counterpart.
    Kim YI; Kim JH; Lee TY; Lee KW
    J Ocul Pharmacol Ther; 2015; 31(6):335-9. PubMed ID: 26133057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimating The Cost Of Delayed Generic Drug Entry To Medicaid.
    Dave CV; Sinha MS; Beall RF; Kesselheim AS
    Health Aff (Millwood); 2020 Jun; 39(6):1011-1017. PubMed ID: 32479219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.
    Kesselheim AS; Stedman MR; Bubrick EJ; Gagne JJ; Misono AS; Lee JL; Brookhart MA; Avorn J; Shrank WH
    Drugs; 2010 Mar; 70(5):605-21. PubMed ID: 20329806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Place of excipients in systemic drug allergy.
    Barbaud A
    Immunol Allergy Clin North Am; 2014 Aug; 34(3):671-9, x. PubMed ID: 25017684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program.
    Witt DM; Tillman DJ; Evans CM; Plotkin TV; Sadler MA
    Pharmacotherapy; 2003 Mar; 23(3):360-8. PubMed ID: 12627935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population-based study.
    Corrao G; Soranna D; Merlino L; Mancia G
    Eur J Clin Invest; 2014 Oct; 44(10):933-9. PubMed ID: 25132063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex.
    Navarro-Artieda R; Rejas-Gutiérrez J; Pérez-Paramo M; Sicras-Mainar A
    Neurologia (Engl Ed); 2018 Apr; 33(3):141-153. PubMed ID: 27321171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.